[1] VETTER MH, HAYS JL. Use of targeted therapeutics in epithelial ovarian cancer: a review of current literature and future directions[J]. Clin Ther, 2018, 40(3): 361. doi: 10.1016/j.clinthera.2018.01.012
[2] ENDO H, HAMA N, BAGHDADI M, et al. Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression[J]. Int Immunol, 2020, 32(3): 175. doi: 10.1093/intimm/dxz074
[3] NAMEE NM, ODRISCOLL L. Extracellular vesicles and anti-cancer drug resistance[J]. Biochim Biophys Acta, 2018, 12(2): 123.
[4] 谢蓉蓉, 孙福强. 天然产物二氢杨梅素的研究进展[J]. 广东药科大学学报, 2019, 35(3): 470.
[5] LE L, JIANG B, WAN W, et al. Metabolomics reveals the protective of Dihydromyricetin on glucose homeostasis by enhancing insulin sensitivity[J]. Sci Rep, 2016, 6: 36184. doi: 10.1038/srep36184
[6] ZHANG X, WANG L, PENG L, et al. Dihydromyricetin protects HUVECs of oxidative damage induced by sodium nitroprusside through activating PI3K/Akt/FoxO3a signalling pathway[J]. J Cell Mol Med, 2019, 23(7): 4829. doi: 10.1111/jcmm.14406
[7] DONG S, JI J, HU L, et al. Dihydromyricetin alleviates acetaminophen-induced liver injury via the regulation of transformation, lipid homeostasis, cell death and regeneration[J]. Life Sci, 2019, 227: 20. doi: 10.1016/j.lfs.2019.04.019
[8] FENG QW, CUI ZG, JIN YJ, et al. Protective effect of dihydromyricetin on hyperthermia-induced apoptosis in human myelomonocytic lymphoma cells[J]. Apoptosis, 2019, 24(3/4): 290.
[9] TAN M, JIANG B, WANG H, et al. Dihydromyricetin induced lncRNA MALAT1TFEB-dependent autophagic cell death in cutaneous squamous cell carcinoma[J]. J Cancer, 2019, 10(18): 4245. doi: 10.7150/jca.32807
[10] SUN Y, WANG C, MENG Q, et al. Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca -mediated apoptosis pathways in MCF-7/ADR and K562/ADR[J]. J Cell Physiol, 2018, 233(4): 3066. doi: 10.1002/jcp.26087
[11] HANAHAN D, WEINBERG RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646. doi: 10.1016/j.cell.2011.02.013
[12] GIANSANTI V, TORRIGLIA A, SCOVASSI AI. Conversation between apoptosis and autophagy: "Is it your turn or mine?"[J]. Apoptosis, 2011, 16(4): 321. doi: 10.1007/s10495-011-0589-x
[13] HASNAT M, YUAN Z, ULLAH A, et al. Mitochondria-dependent apoptosis in triptolide-induced hepatotoxicity is associated with the Drp1 activation[J]. Toxicol Mech Methods, 2020, 30(2): 124. doi: 10.1080/15376516.2019.1669247
[14] KONTOS CK, CHRISTODOULOU MI, SCORILAS A. Apoptosis-related BCL2-family membem: Key players in chemotherapy[J]. Anti Cancer Agents Med Chem, 2014, 14(3): 353. doi: 10.2174/18715206113139990091
[15] DENG B, SU F, XIE R, et al. MiR-371-5p suppresses the proliferative and migratory capacity of human nasopharyngeal carcinoma by targeting BCL2[J]. Oncol Lett, 2018, 15(6): 9209.
[16] 张琼, 甘怀勇, 武世伍. WWOX与ERK1在食管鳞状细胞癌中表达及其临床病理意义[J]. 蚌埠医学院学报, 2020, 45(10): 1313.
[17] SAMMONS RM, PERRY NA, LI Y, et al. A novel class of common docking domain inhibitors that prevent ERK2 activation and substrate phosphorylation[J]. ACS Chem Biol, 2019, 14(6): 1183. doi: 10.1021/acschembio.9b00093
[18] 荆薇, 张晔, 刘云鹏, 等. ERK通路对胃癌细胞顺铂敏感性的调节作用[J]. 世界华人消化杂志, 2009, 17(28): 2931.